Introduction
============

Age-related macular degeneration (AMD) is a complex and widespread disease that represents a public health problem and a significant challenge for current economic models. The general consensus states that as the population grows and ages, the incidence of the disease will increase as well. Major breakthroughs have been made in the past decades in treating the wet form of AMD and near-term prognosis has improved significantly. Despite every effort, AMD therapy is still not able to prevent or cure this pathology. While preventive genetic screening and counseling are under supervision and may be important parts of preventive medicine, there is a growing need for new treatment options for AMD. In this review, we focus on dry AMD. It accounts for 80% of all intermediate and advanced forms of the disease. Although vision loss is mainly due to the wet form (75%), dry AMD remains a challenge for ophthalmologists because of the lack of effective therapies. Actual management of this form is only based on lifestyle modification, vitamin supplements, and supportive measures in the advanced stages.

This article reviews the epidemiological and pathological features, as well as current and potential treatment approaches, of dry AMD.

Epidemiology, etiology, natural history, and prognosis of dry AMD
=================================================================

Epidemiology
------------

AMD is a disorder of the central part of the retina -- macula -- causing progressive impairment of central vision.

It is considered the leading cause of visual disability and blindness in people over 60 years of age in many Western countries, with severe vision loss occurring in approximately 10%--15% of people with AMD. Allikmets et al[@b1-opth-9-563] found that AMD affects at least eleven million people in the USA and 1.2 million people are legally blind as a result of the disease.

Dry AMD, also called geographic atrophy (GA), is characterized by outer retinal and retinal pigment epithelium (RPE) atrophy and accounts for 80% of all intermediate and advanced forms of the disease. Wet AMD -- neovascular, exudative -- is caused by choroidal neovascularization growth under the RPE and the retina, exudative hemorrhages and disciform scarring. Vision loss is mainly due to neovascular AMD (75%) rather than dry AMD (25%).[@b2-opth-9-563] The 5-year incidence of advanced AMD, as reported in one of the most important population-based studies -- the Beaver Dam Eye Study -- appears to be 0.9%, with neovascular AMD affecting 0.6% of eyes among the general population and dry AMD developing in 0.3% of cases. Age seems to be the most important risk factor. The prevalence of AMD is approximately 0% at 50 years, then rises to 2% at 70 years and to 6% by the age of 80 years, as stated by Zarbin.[@b3-opth-9-563] This part of the population is expected to grow within the next decade, and by 2020, nearly 50% of the population in the Western world will have AMD.[@b4-opth-9-563] Early AMD is usually associated with vision impairment, while late-AMD patients have more severe or even complete vision loss.

Etiology
--------

Apart from age, MD is a complex multifactorial disease, wherein individual genetic susceptibilities -- together with environmental factors and metabolic conditions -- contribute to the clinical manifestations of the disorder. Smoking is the second most significant risk factor, especially for dry AMD (odds ratio \[OR\]: 4.5), suggesting a chronic reduction in oxygen supply due to a reduction of blood and tissue oxygen partial pressure (pO2), along with a tendency to ischemic injury.[@b5-opth-9-563]

Clemons et al[@b6-opth-9-563] reported in the Age-Related Eye Disease Study (AREDS, 2005) that the prevalence of AMD is higher in white than in nonwhite people. Contrasting results regarding other risk factors, such as sex or chronic light exposure, have been reported over the years.[@b7-opth-9-563]--[@b9-opth-9-563]

The hallmark of AMD is the presence of drusen. Drusen are classified as basal linear deposits (BlinD), basal laminar deposits (BlamD), and drusen.[@b10-opth-9-563]--[@b12-opth-9-563] They consist of debris accumulated between RPE cells and Bruch's membrane. BlamD and BlinD are very small and can be observed only histologically, by light or electron microscopy. Drusen, instead, are easily seen during a fundus oculi slit-lamp examination. They are bigger, round shaped, and yellowish. Two different drusen types can be observed. Hard drusen, smaller and with clear margins, may be present both in normal aging eyes and in AMD eyes.[@b13-opth-9-563] In some diseases, such as MDs, long-standing retinal detachment, choroidal nevi, or others, we can find some punctuate deposits that look like hard drusen. Histologically, they share some but not all components with drusen, probably accounting for a different etiopathogenesis.[@b14-opth-9-563] Although hard drusen can be found in 95% of the aged population, they are more common in dry AMD, and when associated with retinal pigment alterations and/or soft drusen, the risk of progression is increased.[@b2-opth-9-563],[@b5-opth-9-563],[@b15-opth-9-563] Soft drusen are bigger and with indistinct margins. They represent a major risk factor for AMD evolution to advanced stages, both neovascularization and GA.[@b16-opth-9-563] Most of drusen components are released by the RPE, the neural retina, the choroidal cells, and extraocular sources and all contribute to drusen formation.[@b17-opth-9-563]--[@b19-opth-9-563] The origin of drusen is not fully understood, though several hypotheses coexist: the question whether they are derived from the RPE or the choroidal vasculature still remains unanswered. Currently, evidence suggests that both structures contribute to its formation.[@b5-opth-9-563] RPE dysfunction and failure of phagocytosis result in debris accumulation in the extracellular space. Alterations of choroidal permeability lead to the same accumulation.

Epidemiological studies suggest that oxidative stress is associated with both the incidence and the progression of AMD. In fact, even though oxidative stress is one of the physiological changes that presents with aging, it is an important cause of retinal damage progression in AMD, as proved in the AREDS, wherein antioxidant supplementations were able to prevent the progression of intermediate and late forms of the disease.[@b5-opth-9-563],[@b6-opth-9-563]

Growing evidence suggests that AMD is downstream of a chronic inflammatory condition wherein activation of the immune system plays an important role. Metabolic products accumulate in the extracellular space between Bruch's membrane and the RPE, activating the complement system with a significant increase in oxidative stress, similar to what happens in atherosclerosis or Alzheimer's disease (AD). A variety of drusen components have been recognized: proteins (major histocompatibility complex-II, β-amyloid, apolipoproteins A and E, cytokines, and fibronectin), phospholipids, lipofuscin, advanced glycation end products, and acute-phase proteins that can activate the complement system in response to infections (*Chlamydia pneumoniae*).[@b20-opth-9-563],[@b21-opth-9-563] An important regulatory complement protein is complement factor H (CFH), a major inhibitor of the alternative complement cascade that prevents the complement components from excessive activation to different stimuli; CFH is synthesized by RPE cells.

Recent studies have demonstrated that a certain polymorphism of a gene in chromosome 1 that encodes CFH would increase the risk of AMD. This higher susceptibility is observed when a tyrosine amino acid 402 is substituted by a histidine and such a variant may explain up to 50% of AMD cases.[@b15-opth-9-563],[@b20-opth-9-563]

Genetic variants of *CFH* are associated with a higher risk of AMD. A heterozygous mutation confers a two- to four-fold increased risk, whereas a homozygous mutation augments it to five- to seven-fold.

Epidemiological studies suggest that oxidative stress is able to increase both the incidence and the progression of AMD.

Furthermore, antioxidant supplementations were able to prevent the progression of intermediate and late forms of the disease.[@b5-opth-9-563],[@b6-opth-9-563]

Natural history and prognosis
-----------------------------

Nonexudative AMD has a better prognosis compared to wet AMD.[@b22-opth-9-563] GA tends to enlarge over time at variable rates to cover the entire macula, typically sparing the foveal zone until the late stages of the disease. The effect of GA on visual acuity (VA) deterioration is crucial; in fact, atrophy spreads at a median rate of 1.72 mm^2^ per year and it usually takes a number of years from the onset of GA to cause consistent visual loss.[@b23-opth-9-563],[@b24-opth-9-563] The rate of significant visual loss (three or more lines) is reported to be 8% per year.[@b25-opth-9-563] The histopathological analysis of dry AMD shows an alteration of the blood--retinal barrier. RPE cellular components show postmitotic damage, with consequent epithelium involution, photoreceptor loss, atrophy of outer retinal layers, and choroidal degeneration. RPE reacts to this loss of cells with pigment clumps around the area of atrophy, typically hyperfluorescent.[@b22-opth-9-563],[@b26-opth-9-563] Areas of increased autofluorescence are constituted of lipofuscin accumulation within the damaged RPE.[@b23-opth-9-563] Their tendency to enlarge is now considered a prognostic factor for the progression of atrophy and absolute scotoma, therefore for visual loss.

Summary of current management strategies
========================================

Dry AMD management consists of lifestyle modification, vitamin supplements, and supportive measures in advanced stages.

Together with the reduction of body mass index and avoidance of heavy alcohol consumption, lifestyle modifications such as physical activity and quitting smoking are also recommended.

Smoking
-------

With its ability to increase the oxidative stress and to depress the natural antioxidant system, smoking is significantly associated with increased risk of development and progression of AMD (Early AMD, GA, and choroidal neovascularization).

It is known that smoking may slow down choroidal blood flow, promoting ischemia, hypoxia, and microinfarctions, resulting in a reduction of macular pigments and damage of the RPE.

According to a recent review, there is a dose--effect relationship between the number of years smoking/pack-years smoked and the risk of developing AMD.[@b27-opth-9-563]

Physical activity
-----------------

Even though there is no evidence about interactions between active lifestyle and the development of the disease, it is known that physical activity reduces both systemic inflammation and endothelial dysfunction, both of which contribute to AMD pathogenesis.

Alcohol consumption
-------------------

Although alcohol consumption could hypothetically be both harmful and protective for AMD Chong et al[@b28-opth-9-563] in a systematic review and meta-analysis found an increased risk for early AMD in heavy alcohol consumers (OR: 1.47; 95% confidence interval, 1.10--1.95). The association between late AMD and heavy alcohol consumption varied in the four analyzed studies, nonetheless in three of them the correlation was positive. The review could not precisely access the role of moderate alcohol consumption on early AMD.

Obesity
-------

The Atherosclerosis Risk in Communities Study states that middle-aged people with a waist--hip ratio reduction over time were less likely to develop AMD, particularly those who were initially obese.[@b29-opth-9-563]

Diet
----

The 10-year incidence of AMD in The Blue Mountain Eye Study and the Alienor Study confirmed that there is a decreased risk for AMD in patients with high intake of long-chain omega-3 polyunsaturated fatty acids.[@b30-opth-9-563]

Dietary supplementation has been thoroughly investigated by AREDS 1 and 2 and their results will be discussed in the next section.

Supportive measures
-------------------

Low-vision rehabilitation is the best option when medical or surgical treatments are unsuccessful or contraindicated. Typical supportive measures include assessment of residual functions and functional vision, identification of preferred retinal loci and training in their active use, prescription and training in the use of low-vision aids, training and educational programs (orientation and mobility), and assistance with daily activities. A systematic review underlines the fact that in the absence of adequate clinical trials, it is impossible to form stronger conclusions regarding the most effective low-vision interventions for individuals with AMD.[@b31-opth-9-563] Some authors state that augmented low-vision rehabilitation programs are as effective in improving activities of daily living or quality of life as conventional in-clinic rehabilitation programs.[@b32-opth-9-563]

Review of recent developments in dry AMD management
===================================================

Regarding dietary supplementation, the two most important studies are the AREDS and the AREDS 2.[@b33-opth-9-563],[@b34-opth-9-563]

In the AREDS, the following different antioxidants were administered: vitamin C (500 mg), vitamin E (400 international units \[IU\]), beta-carotene (15 mg), zinc (80 mg), and copper (2 mg).

Antioxidants
------------

As the retina is particularly susceptible to oxidative stress, the use of antioxidants may prevent its damage due to reactive oxygen species. The latter play a role in modulating the nuclear factor erythroid 2-related factor 2, involved in the regulation of expression of genes encoding antioxidant proteins.[@b35-opth-9-563]

Zinc
----

The development of the disease seems to be influenced by a dysregulation and excessive activation of the complement cascade, leading to accumulation of sub-RPE deposits.

Klevering[@b36-opth-9-563] in a recent study highlighted that daily zinc supplements for 3 months during AMD could lower the excessive systemic complement activation. However, the benefit of zinc is still debated and a recent meta-analysis confirmed that available data about its role in prevention of AMD are inconclusive.[@b37-opth-9-563]

Copper
------

This essential element was evaluated in the AREDS, but its role as a protective agent remains uncertain. In order to avoid a copper deficiency anemia due to zinc intake, this essential trace element, a scavenger of free radicals, has been added in the AREDS. Anyway, its role in AMD protection is still uncertain.[@b38-opth-9-563]

In AREDS, there was a statistically significant reduction in odds for the development of advanced AMD with the use of antioxidants (vitamin C, vitamin E, and beta-carotene,) plus zinc and copper. In particular, this reduction was more significant in eyes with extensive intermediate drusen, GA not involving the center of the macula, or at least one large drusen (AREDS category 3) and in people with advanced AMD or VA less than 20/32 in one eye (AREDS category 4).[@b33-opth-9-563]

A systematic review and meta-analysis by Chong et al[@b39-opth-9-563] suggested that vitamin A, vitamin C, vitamin E, zinc, lutein, zeaxanthin, alpha- and beta-carotene, beta-cryptoxanthin, and lycopene had little or no effect in the primary prevention of early AMD. In a systematic review in 2008, the same authors reported that the consumption of omega-3 polyunsaturated fatty acids, such as docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), show protective effects against the progression of AMD.[@b40-opth-9-563]

The randomized controlled trial AREDS 2, published in 2013, investigated the risk of progression from early to advanced AMD.

Three different formulations were evaluated: one without beta-carotene (due to an increased risk of lung cancer in smokers and former smokers), another one with a lower dose of zinc (25 mg), and the third one with both these conditions. Lower dose of zinc was chosen because of the risk of gastrointestinal and genitourinary diseases that zinc itself can induce and because its absorption has been found to be the same even with lower doses.[@b34-opth-9-563] The results showed that the addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation had no positive effect on the progression to advanced AMD.

The difference between low-dose versus high-dose zinc was not statistically significant, but lutein + zeaxanthin may be a useful carotenoid substitute in the AREDS formulation in smokers and former smokers ([Table 1](#t1-opth-9-563){ref-type="table"}).[@b34-opth-9-563]

Recent studies discuss the possible positive effects of other antioxidants, vitamins, and minerals ([Table 2](#t2-opth-9-563){ref-type="table"}).

Crocetin
--------

It is a natural carotenoid dicarboxylic acid, found in saffron, which seems to inhibit caspase activity, reduce the oxidative stress, and protect the retinal tissue from exposure to damaging light in experimental models.[@b41-opth-9-563] Beyond its antioxidative power, evidence shows that short-term saffron supplementation improves retinal flicker sensitivity in early AMD.[@b42-opth-9-563]

Curcumin
--------

It can reduce lipid peroxidation and formation of reactive oxygen species.[@b43-opth-9-563] Its effect on RPE was demonstrated in in-vitro models only. In a recent article, Chang et al[@b44-opth-9-563] used RPE-like cells derived from pluripotent stem cells from patients with dry AMD. Pretreatment with curcumin had a cytoprotective effect against the oxidative stress of H~2~O~2~ through the reduction of H~2~O~2~-induced cell death and reduced reactive oxygen species levels. Furthermore, curcumin modulated the expression of many oxidative stress-regulating genes, such as platelet-derived growth factor, vascular endothelial growth factor (*VEGF*), heme oxygenase 1, and others.[@b44-opth-9-563]

Vitamins B9, B12, and B6
------------------------

These are currently under study in the prevention of AMD but their roles are still uncertain. Beyond their antioxidative powers, they can decrease the serum homocysteine level, reducing the risk of vascular diseases.

Christen et al[@b45-opth-9-563] in a recent randomized trial, stated that participants who took daily supplements of folic acid (vitamin B9), pyridoxine (vitamin B6), and cyanocobalamin (vitamin B12) had a decreased risk of AMD.

The richest sources of resveratrol (3,4,5-trihydroxystilbene) are grape skin and seeds, having well known antiaging, anticancer, and cardioprotective properties. In in vitro models of RPE cells, these effects seem to be present through the inhibition of mitogen-activated protein kinase/extracellular signal-regulated protein kinase and the VEGF expression.[@b46-opth-9-563],[@b47-opth-9-563]

Key concepts of dry AMD
-----------------------

-   Reducing risk factors and providing lifestyle modifications are management strategies that can prevent development and progression of the disease.

-   To date, antioxidant supplementation together with intake of some essential elements did not prove effective in primary prevention of AMD.

-   In two randomized controlled trials, the use of antioxidants plus zinc and copper was able to reduce the risk of progression to advanced AMD (in AREDS) and the antioxidant carotenoid could be replaced by lutein and zeaxanthin in smokers and former smokers (in AREDS 2).

-   New therapeutic approaches target drusen formation, inflammation, oxidative stress, accumulation of toxic by-products, choroidal perfusion, RPE cells, and photoreceptors.

-   Future developments in genetics could clarify individual susceptibilities and new targeted therapies.

Future research and directions
==============================

To date, the only therapy available for early AMD and GA is daily intake of antioxidant formulations.

New knowledge in AMD molecular pathogenesis can help us to identify possible therapeutic targets to reduce/stop the stimuli of continuous damage or even to replace, repair, or regenerate the damaged cells.

New strategies are based on the following: Reduce or block drusen formation.Reduce or eliminate inflammation.Lower the accumulation of toxic by-products from visual cycle.Reduce or eliminate retinal oxidative stress.Improve choroidal perfusion.Replace, repair, or regenerate lost RPE cells and photoreceptors.Gene therapy.

Reduce or block drusen formation
--------------------------------

Drusen, both hard and soft, are easily seen during a fundus oculi slit-lamp examination. Almost no cases of AMD exist without prior drusen formation, and the rate of progression correlates with the number and size of drusen. Moreover, GA progression is correlated to drusen regression.[@b48-opth-9-563],[@b49-opth-9-563] Whether they represent a cause or a consequence of the disease is still unclear. New theories postulate that drusen could be an adaptive process, to confine elements potentially detrimental to the retina.[@b50-opth-9-563] How drusen are formed is not still clear: probably there is a dysregulation of the pathways responsible for proteins and cellular debris degradation (lysosomic and autophagic processes), which allows their aggregation on the retina.[@b51-opth-9-563] In addition, RPE cells are physiologically exposed to continuous oxidative stress, so they have a rapid turnover. The inflammatory response, together with the immune system, reacts to accumulation of waste material, creating chronic local inflammation that represents a nucleating site for the deposition of extracellular elements.[@b52-opth-9-563]

The new therapeutic approach aims to stop disease progression, selectively blocking or slowing down the accumulation of the singular drusen components ([Tables 3](#t3-opth-9-563){ref-type="table"} and [4](#t4-opth-9-563){ref-type="table"}).

Several studies have shown a correlation between AMD drusen and AD plaques. Both contain amyloid-β (Aβ), in strong association with activated complement components.[@b53-opth-9-563]--[@b55-opth-9-563] Aβ is thought to be an activator of the complement system and could be a potential target for new therapies.[@b51-opth-9-563] Humanized monoclonal antibodies directed against Aβ have been tested in mouse models, demonstrating that systemic immunotherapy reduces the accumulation of amyloid and complement components (C3) in the retina, improves functional response, and obtains structural preservation of RPE cells.[@b56-opth-9-563]--[@b58-opth-9-563] Two different humanized monoclonal antibodies are now under evaluation in clinical trials: RN6G (Pfizer, New York, NY, USA) and GSK933776 (GlaxoSmithKline, Verona, Italy).

Another drug called glatiramer acetate has been shown to be able to reduce AD plaques in mice.[@b59-opth-9-563] The same effect has been demonstrated on drusen in mouse models of AMD.[@b60-opth-9-563],[@b61-opth-9-563] Clinical trials on glatiramer acetate and dry AMD are ongoing.

Reduce or eliminate inflammation
--------------------------------

Many complement components and inflammatory molecules are found in drusen. Several genetic studies show a link between complement-related proteins and AMD risk.[@b62-opth-9-563] The alternative complement pathway is thought to be the most involved.[@b21-opth-9-563],[@b63-opth-9-563] Modulating the complement factors may reduce their excessive activation and the subsequent immune-mediated damage to the RPE.

Good results have been shown in the context of intravitreal administration of an antibody against complement factor D, called lampalizumab (FCFD4514S; Genentech Inc, Roche, San Francisco, CA, USA). A phase 2 study has been recently completed, showing good results: 20.4% reduction in GA progression at month 6 and month 18, with an acceptable safety profile.[@b64-opth-9-563]

Anti-complement component 5 (C5) antibodies are also under evaluation for intravitreal administration: LFG316 (Novartis, Basel, Switzerland), ARC1905 (Ophthotech, Princeton, NJ, USA), and eculizumab (Soliris^®^; Alexion Pharmaceuticals, Cheshire, CT, USA). As drusen formation triggers chronic local inflammation, anti-inflammatory drugs represent another possible therapeutic strategy. Fluocinolone acetonide (Iluvien™; Alimera Sciences, Alpharetta, GA, USA) is a nonbioerodible polyamide tube containing corticosteroid with a broad anti-inflammatory target. An ongoing phase 2 study aims to evaluate intravitreal administration in GA (Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy).

Some studies have also considered rapamycin, which is a macrolide with anti-inflammatory activity. Two studies, phase 1 and phase 2, have recently been completed, evaluating subconjunctival (Pilot Study of the Evaluation of Subconjunctival Sirolimus in the Treatment of Bilateral GA Associated With AMD, SIRGA) or intravitreal (Sirolimus for Advanced Age-Related Macular Degeneration, SIRGA2) administration of the drug, but the results show that it does not prevent GA progression.[@b65-opth-9-563] Conversely, it seems to be associated with detrimental effect on VA.

Many other drusen components could be potential targets for dry AMD therapy, but studies are still at a preclinical stage.[@b66-opth-9-563] For example, microglia and macrophages, in order to modulate its recruitment to the site of injury, or mast cells, to prevent its degranulation.[@b67-opth-9-563],[@b68-opth-9-563] To date, our knowledge on the role of inflammation and immune system is fairly advanced. It remains still unclear if they are protectors or drivers of retinal degeneration. Maybe this lack of understanding can explain the great amount of immune therapy failure in AMD. More efforts are needed to better identify new therapeutic strategies based on specific and well-known targets.[@b50-opth-9-563]

Lipids are also found in drusen and several studies demonstrate that lipids accumulate at the site of subsequent formation of AMD deposits. This accumulation has a detrimental effect on RPE because the oxidative stress over time results in the formation of lipid peroxidation products that cannot be digested by lysosomes.[@b69-opth-9-563] Similar to atherosclerotic plaques, these accumulations may contribute to the adverse effects on RPE structure and function.[@b70-opth-9-563],[@b71-opth-9-563]

To date, the role of lipid metabolism in AMD is poorly understood, but it is clear that lowering lipid accumulation in Bruch's membrane could be an efficient strategy to treat AMD in the first phases. In fact, some authors have evaluated statin efficacy in AMD. Unfortunately, the results are inconclusive, as reported in a recent Cochrane review.[@b72-opth-9-563]

Lower the accumulation of toxic by-products from visual cycle
-------------------------------------------------------------

The aim is to slow down photoreceptor activity to reduce the accumulation of their toxic by-products, such as N-retinylidene-N-retinylethanolamine (A2-E) and lipofuscin, preventing death of RPE and photoreceptor cells. These drugs are still in phase 2 studies (fenretinide and ACU-4429) or preclinical stage (ALK-001) but represent an exciting possibility for treating AMD.

Fenretinide
===========

Fenretinide (RT-101; ReVision Therapeutics, San Diego, CA, USA) decreases the blood pool of vitamin A, which is the base for A2-E biosynthesis. Fenretinide has shown antiangiogenic and anti-inflammatory properties too.[@b73-opth-9-563]

ACU-4429
========

ACU-4429 (Acucela, Inc, Seattle, WA, USA), in experimental models, decreases the accumulation of A2-E, modulating the enzyme RPE65 that converts *trans*-retinol to *cis*-retinol within the RPE and slowing down the visual cycle.

ALK-001
=======

ALK-001 (Alkeus Pharmaceuticals, Boston, MA, USA) is a modified vitamin A, which avoids the dimerization of vitamin A molecules to form A2-E and lipofuscin.[@b49-opth-9-563]

Reduce or eliminate retinal oxidative stress
--------------------------------------------

Neuroprotective drugs preserve macular function by preventing apoptosis of viable RPE cells and photoreceptors. Several drugs are under investigation, such as ciliary neurotrophic factor (CNTF), brimonidine tartrate, and tandospirone, but none of them has shown a significant efficacy at the moment.

CNTF
====

CNTF was developed as an intravitreal sustained-release device for retinitis pigmentosa, and it is now studied for treating AMD. In animal models, it was shown to inhibit photoreceptor cell apoptosis. In a phase 2 clinical trial (NT501, Renexus, Cumberland, RI, USA) in patients with GA, its effect in preserving VA has been demonstrated, but without any significant difference from the sham group. No benefit in terms of the progression of lesion was found.[@b74-opth-9-563]

Brimonidine tartrate
====================

This alpha-2 adrenergic receptor agonist is able to stimulate the production of neurotrophic factors and protect photoreceptor cells in animal models of retinal degeneration.[@b75-opth-9-563] It is now being evaluated in a phase 2 clinical trial as an intravitreal implant (posterior-segment drug delivery system, Allergan, Irvine, CA, USA).

Tandospirone
============

Tandospirone (AL-8309B; Alcon, Fort Worth, TX, USA) is a selective serotonin 1A agonist protecting the retina from photooxidative stress. It has been used as a topical ophthalmic solution in GA, in a phase 3 trial, but discontinued in 2012 owing to its lack of efficacy.[@b76-opth-9-563]

Improve choroidal perfusion
---------------------------

The choroid provides oxygen and nourishment to the outer retinal layers. Impairment in choroidal blood flow is one of the supposed pathogenetic mechanisms of AMD. Several drugs have been tested, but none has demonstrated efficacy: eg, trimetazidine, MC-1101, sildenafil, and moxaverine.

Trimetazidine
=============

Trimetazidine is currently used to treat angina. In a recent study, it failed in slowing down the progression of GA.[@b77-opth-9-563]

MC-1101
-------

MC-1101 (MacuCLEAR, Inc, Plano, TX, USA) has anti-inflammatory and antioxidative properties and it is supposed to increase choroidal blood flow. A phase 1 study highlighted that patients with AMD using MC-1101 had a modest increase in choroidal blood flow within 2 hours postdosing.

Moxaverine
==========

Moxaverine[@b78-opth-9-563] is a phosphodiesterase inhibitor that increases choroidal mean flow velocity in the ophthalmic artery and in posterior ciliary arteries. Its role in dry AMD needs to be investigated.

Sildenafil
==========

Sildenafil is effective on retinal vessels,[@b79-opth-9-563] but no improvement in choroidal blood flow has been found.

Replace, repair, or regenerate lost RPE cells and photoreceptors
----------------------------------------------------------------

Due to its high metabolic activity, the RPE represents an ideal tissue for transplantation in AMD.

Several strategies, either allogeneic or autologous, have been tried to transplant RPE cells in degenerated areas, without great success due to[@b80-opth-9-563] graft rejection, poor viability of cells, and complex attachment to the Bruch's membrane.

New promising approaches employ embryonic stem cells isolated from human blastocysts. In vitro, they are pluripotent and so are able to differentiate in RPE cells if adequately stimulated. Several surgical approaches to transplant these cells have been used in ongoing clinical trials.[@b81-opth-9-563]

But what if the photoreceptor cells are dead? A new frontier is now represented by the simultaneous transplantation of photoreceptors and RPE cells.[@b81-opth-9-563] Rod precursors, obtained from both developing retina and human embryonic stem cells, have been used in animal models. Transplantation of rod precursors has shown improved vision in mice that lack rod function.[@b82-opth-9-563],[@b83-opth-9-563]

Gene therapy
------------

Genomic findings of the past have identified many genes associated with AMD, such as *CFH* or age-related maculopathy susceptibility 2 (*ARMS2*[@b81-opth-9-563]). To date, genetics has helped us in the risk prediction of disease development/progression, but our knowledge is still incomplete. Future developments could lead us to use genetic analysis to assess patient response to therapy, thus helping us to choose the most efficient treatment option.[@b84-opth-9-563],[@b85-opth-9-563]

Conclusion
==========

In general terms, therapeutic approaches to GA should be aimed at reducing or blocking the noxious stimuli, protecting the remaining cells, and further repairing, replacing, or regenerating the damaged ones. Current and continuing advances in understanding the molecular pathogenesis of early AMD and GA are identifying new relevant therapeutic targets, coupled with the advances in detecting and measuring disease progression. Breakthroughs in developing therapies that block and/or reverse early AMD and GA are expected. While there are many challenges and unmet needs in understanding and treating early and atrophic AMD, this is an exciting time to be working in this area.
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###### 

Characteristics of AREDS 1 and AREDS 2[@b33-opth-9-563],[@b34-opth-9-563]

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                  AREDS 1                                                                                                                      AREDS 2                                                                                                                                        
  ------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------ -----------------------
  Period                                                                          1992--2001                                                                                                                   2006--2012                                                                                                                                     

  Design                                                                          Multicenter, phase 3, randomized controlled clinical trial                                                                   Multicenter, phase 3, randomized controlled clinical trial                                                                                     

  Participants                                                                    3,609 eligible[\*](#tfn1-opth-9-563){ref-type="table-fn"}                                                                    4,186 eligible                                                                                                                                 

  Average follow-up                                                               6.3 years                                                                                                                    5 years                                                                                                                                        

  Enrollment criteria                                                             -- Extensive small drusen, intermediate drusen, large drusen, noncentral GA, or pigment abnormalities in one or both eyes\   -- Bilateral large drusen or nonfoveal GA\                                                                                                     
                                                                                  -- Advanced AMD or vision loss due to AMD in one eye\                                                                        -- Large drusen or nonfoveal GA in one eye and advanced AMD in the fellow eye                                                                  
                                                                                  -- At least one eye had best-corrected visual acuity of 20/32 or better                                                                                                                                                                                                     

  Randomization                                                                   Supplementation                                                                                                              Primary                                                                                       Secondary                                        

  1\. Antioxidants: vitamin C, 500 mg; vitamin E, 400 IU; beta-carotene, 15 mg\   1\. Lutein, 10 mg; zeaxanthin, 2 mg\                                                                                         1\. AREDS 1 formulation unchanged\                                                                                                             
  2. Zinc, 80 mg; and copper, 2 mg;\                                              2. ω-3 LCPUFAs: DHA, 350 mg; EPA, 650 mg\                                                                                    2. AREDS 1 formulation with zinc, 25 mg\                                                                                                       
  3. Antioxidants plus zinc\                                                      3. Combination of 1 and 2\                                                                                                   3. AREDS 1 formulation without beta-carotene\                                                                                                  
  4. Placebo                                                                      4. Placebo                                                                                                                   4. Combination of 2 and 3                                                                                                                      

  Primary outcomes                                                                1\. Photographic assessment of progression to or treatment for advanced AMD\                                                 1\. Photographic assessment of progression to advanced AMD                                                                                     
                                                                                  2. At least moderate visual acuity loss from baseline (≥15 letters)                                                                                                                                                                                                         

  Secondary outcomes                                                              1\. Visual acuity loss attributable to AMD\                                                                                  1\. Effect of the primary randomization supplements on progression to moderate vision loss\                                                    
                                                                                  2. Marked visual acuity loss\                                                                                                2. Effect of the primary randomization supplements on progression of lens opacity\                                                             
                                                                                  3. Visual acuity loss in eyes with advanced AMD at baseline\                                                                 3. Effect of the primary randomization supplements on vision\                                                                                  
                                                                                  4. Development of neovascular AMD\                                                                                           4. Effect of the variations of the AREDS 1 supplements on progression to advanced AMD\                                                         
                                                                                  5. Development of GA in the center of the macula[\*\*](#tfn2-opth-9-563){ref-type="table-fn"}\                               5. Effect of the variations of the AREDS supplements on progression to moderate vision loss                                                    
                                                                                  6. Progression of AMD in category 2 participants                                                                                                                                                                                                                            

  Results                                                                         **AMD progression**                                                                                                          **AMD progression in primary randomization**                                                                                                   

  **Groups**                                                                      **Risk reduction in AMD categories 2, 3 and 4**                                                                              **Risk reduction in AMD categories 3 and 4**                                                  **Groups**                                       **Risk reduction**

  Antioxidants vs no antioxidants                                                 Nonsignificant                                                                                                               Nonsignificant                                                                                Lutein + zeaxanthin vs placebo                   Nonsignificant

  Zinc vs no zinc                                                                 Suggestive                                                                                                                   Significant                                                                                   DHA + EPA vs placebo                             Nonsignificant

  Antioxidants vs placebo                                                         Nonsignificant                                                                                                               Nonsignificant                                                                                Lutein + zeaxanthin + DHA + EPA vs placebo       Nonsignificant

  Zinc vs placebo                                                                 Suggestive                                                                                                                   Significant                                                                                                                                    

  Antioxidants + zinc vs placebo                                                  Significant                                                                                                                  Significant                                                                                                                                    

  **Visual acuity loss**                                                          **AMD progression in secondary randomization**                                                                                                                                                                                                                              

  **Groups**                                                                      **Risk reduction in AMD categories 2, 3 and 4**                                                                              **Risk reduction in AMD categories 3 and 4**                                                  **AREDS 1 supplement groups**                    **Effect**

  Antioxidants vs no antioxidants                                                 Nonsignificant                                                                                                               Nonsignificant                                                                                Low-dose zinc vs original                        Nonsignificant effect

  Zinc vs no zinc                                                                 Nonsignificant                                                                                                               Nonsignificant                                                                                No beta-carotene vs original                     Nonsignificant effect

  Antioxidants vs placebo                                                         Nonsignificant                                                                                                               Nonsignificant                                                                                Low-dose zinc and no beta-carotene vs original   Nonsignificant effect

  Zinc vs placebo                                                                 Nonsignificant                                                                                                               Nonsignificant                                                                                                                                 

  Antioxidants + zinc vs placebo                                                  Suggestive                                                                                                                   Significant                                                                                                                                    
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Study participants enrolled in the AMD clinical trial;

From point 1 to 5, the analysis of secondary outcomes was restricted to AREDS categories 3 and 4.

**Abbreviations:** AREDS, Age-Related Eye Disease Study; AMD, age-related macular degeneration; DHA, docosahexaenoic acid, EPA, eicosapentaenoic acid; GA, geographic atrophy; IU, international units; LCPUFA, long-chain polyunsaturated fatty acids.

###### 

New antioxidants in dry AMD therapy

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nutrients and elements     Effect                                                                                                                                                                            Efficacy
  -------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------
  Crocetin                   Reduces apoptosis\                                                                                                                                                                Animal models[@b41-opth-9-563]\
                             Increases oxygen diffusion through plasma\                                                                                                                                        Humans (uncertain)[@b42-opth-9-563]
                             Reduces lipid peroxidation\                                                                                                                                                       
                             Upregulates trophic factors                                                                                                                                                       

  Curcumin                   Reduces lipid peroxidation and formation of reactive oxygen species, modulating the expression of many oxidative stress-regulating genes, such as *PDGF, VEGF, HO1*, and others   In vitro models[@b43-opth-9-563],[@b44-opth-9-563]

  Resveratrol                Modulates cell proliferation, apopotosis, and angiogenesis                                                                                                                        In vitro models[@b46-opth-9-563],[@b47-opth-9-563]

  Vitamins B9, B12, and B6   Decrease serum homocysteine level                                                                                                                                                 Humans (uncertain)[@b45-opth-9-563]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AMD, age-related macular degeneration; PDGF, platelet-derived growth factor; VEGF, vascular endothelial growth factor; HO1, heme oxygenase 1.

###### 

Summary of current trials on dry AMD therapy based on drusen components

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of drug               Name of the drug          Way of administration   Reference
  -------------------------- ------------------------- ----------------------- ----------------------------------------------------------------------------------------------------
  Anti-β-amyloid\            RN6G\                     Intravenous\            [ClinicalTrials.gov](http://ClinicalTrials.gov) NCT01577381 (suspended)\
  antibodies                 GSK933776\                Intravenous\            [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT01342926 (ongoing)\
                             Glatiramer acetate        Weekly injection\       [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT00466076 (status unknown)\
                                                       Subcutaneous            [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT00541333 (suspended)

  Anti-C5 antibodies         LFG316\                   Intravitreal\           [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT01255462 (completed, no results available)\
                             ARC1905\                  Intravitreal\           [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT01527500 (recruiting patients)\
                             Eculizumab                Intravitreal\           [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT00950638 (completed, no results available)\
                                                       Intravenous             Results found in "The COMPLETE study" (Yehoshua et al)[@b86-opth-9-563]

  Anti-factor D antibody     Lampalizumab              Intravitreal            Results found in "The MAHALO study" (Mones)[@b64-opth-9-563]

  Anti-inflammatory agents   Fluocinolone acetonide\   Intravitreal\           [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT00695318 (ongoing)\
                             Rapamycin                 Intravitreal\           [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT01675947 (completed, no results available)\
                                                       Subconjuntival\         Results in "The SIRGA study" (Wong et al)[@b65-opth-9-563]\
                                                       Intravitreal            [ClinicalTrials.gov](http://ClinicalTrials.gov). NCT01445548 (completed, results available online)

  Lipids                     Statins                   Oral                    Cochrane review (Gehlbach et al)[@b72-opth-9-563]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AMD, age-related macular degeneration; COMPLETE, COMPLement Inhibition with Eculizumab for the Treatment of NonExudative Age-Related Macular Degeneration; GA, geographic atrophy; SIRGA, Sirolimus in the Treatment of Bilateral GA Associated With AMD.

###### 

Summary of current and future targets of dry AMD therapy based on drusen components

  Targets                                            Strategy                                          Reference
  -------------------------------------------------- ------------------------------------------------- -----------------------------------
  Complement components                              Prevention of activation/accumulation             Anderson et al[@b21-opth-9-563]
  Proteins of acute phase response to inflammation   Modulation/inhibition                             Bowes et al[@b66-opth-9-563]
  Microglia and macrophages                          Modulation of recruitment to the site of injury   Combadiere et al[@b67-opth-9-563]
  Mast cells                                         Prevention of degranulation                       Lutty et al[@b68-opth-9-563]

**Abbreviation:** AMD, age-related macular degeneration.
